Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 0.25 mg/ml - inhalation, conventional - excipient ingredients: polysorbate 20; sodium chloride; dibasic sodium phosphate; water for injections; sorbitan monolaurate; monobasic sodium phosphate - indicationa as at 5th may 1999: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteriod therapy. indications as at 13 july 2000: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteroid therapy). children and adolescents from 4 to 16 years of age: treatment of mild to moderate acute exacerbations of asthma in an outpatient setting.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 1 mg/ml - inhalation, conventional - excipient ingredients: sodium chloride; water for injections; polysorbate 20; monobasic sodium phosphate; dibasic sodium phosphate; sorbitan monolaurate - indications as at 5 may 1999: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteriod therapy. indications as at 13 july 2000: adults and adolescents over 16 years of age: prophylactic management in severe asthma (patients requiring high dose inhaled or oral corticosteroid therapy). children and adolescents from 4 to 16 years of age: treatment of mild to moderate acute exacerbations of asthma in an outpatient setting.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 8 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 20 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 40 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - belimumab, quantity: 200 mg/ml - injection, solution - excipient ingredients: sodium chloride; arginine hydrochloride; histidine hydrochloride monohydrate; histidine; polysorbate 80; water for injections - benlysta is indicated for:,add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g. ana titre greater than or equal to 1:80 and/or anti-dsdna titre greater than or equal to 30 iu/ml) despite standard therapy.,treatment of active lupus nephritis in adult patients who are receiving standard therapy.,the safety and efficacy of benlysta have not been evaluated in patients with severe active central nervous system lupus.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - belimumab, quantity: 200 mg/ml - injection, solution - excipient ingredients: sodium chloride; arginine hydrochloride; histidine hydrochloride monohydrate; histidine; polysorbate 80; water for injections - benlysta is indicated for:,add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g. ana titre greater than or equal to 1:80 and/or anti-dsdna titre greater than or equal to 30 iu/ml) despite standard therapy.,treatment of active lupus nephritis in adult patients who are receiving standard therapy.,the safety and efficacy of benlysta have not been evaluated in patients with severe active central nervous system lupus.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); fluticasone furoate, quantity: 100 microgram - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - copd,breo ellipta is indicated for symptomatic treatment of patients with copd with a fev1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.,breo ellipta is not indicated for the initiation of bronchodilator therapy in copd.,asthma,breo ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,vilanterol, an active ingredient in breo ellipta, is a long-acting beta-2-agonist (laba). a class effect of all labas can be an increased risk of asthma death (see precautions).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone furoate, quantity: 200 microgram; vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram) - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - asthma,breo ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,vilanterol, an active ingredient in breo ellipta, is a long-acting beta-2-agonist (laba). a class effect of all labas can be an increased risk of asthma death (see precautions).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis toxoid, quantity: 16 microgram/ml; pertussis filamentous haemagglutinin, quantity: 16 microgram/ml; pertactin, quantity: 5 microgram/ml; diphtheria toxoid, quantity: 4 iu/ml; tetanus toxoid, quantity: 40 iu/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium phosphate; sodium chloride; water for injections - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older (see section 4.2 dose and method of administration).,boostrix is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see section 4.2 dose and method of administration, section 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties).,the use of boostrix should be in accordance with official recommendations.